Scarica l'app Stockscreener
144.30
0.34%
0.49
Dopo l'orario di chiusura:
144.07
-0.23
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck Co Inc Borsa (MRK) Ultime notizie
Merck (MRK) director receives 55.9149 stock-linked units, payable entirely in cash - Stock Titan
Merck (MRK) director receives 111.8299 stock-linked units, payable 100% in cash after service ends. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 - Business Wire
Merck reports tulisokibart results for Merck & Co. stock - AD HOC NEWS
Merck Says Investigational Skin Therapy Shows Potential - Benzinga
Merck nabs mid-stage trial win for skin disease drug (MRK:NYSE) - Seeking Alpha
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
A Look at Merck & Co Inc (MRK) After 0.4% Gain -- GF Value $120. - GuruFocus
Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Scotiabank - MarketBeat
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline - TradingView
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job? - Yahoo Finance
What Is Driving the Latest Milestones at Merck (NYSE:MRK)? - kalkinemedia.com
Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer DrugMerck & Co (NYSE:MRK) - Benzinga
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - reuters.com
Daiichi, Merck withdraw BLA for B7-H3 ADC in small-cell lung cancer - BioWorld News
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication - TradingView
Merck closes SciBrunch KRAS licence worth up to US$2.13B - Mugglehead Investment Magazine
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor - Business Wire
Merck & Co. stock trades at USD 148.74 after pipeline updates - AD HOC NEWS
B7-H3 ADC Field Opens As Merck & Co. Pulls US Filing - insights.citeline.com
Merck (NYSE:MRK) In Focus As Oncology Advances And Pipeline Readouts Lift Its Shares Toward Rare Heights - kalkinemedia.com
Merck, Daiichi pull US application for second partnered cancer therapy - reuters.com
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years - Benzinga
Merck, Daiichi withdraw ifinatamab FDA application - Mugglehead Investment Magazine
Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading - AD HOC NEWS
Merck stock climbs 2.0 percent ahead of the open - AD HOC NEWS
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
Alpha Buying: Follow the Money From NVIDIA and Merck - Benzinga
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine - Benzinga
What Is Driving the Latest Milestones at Merck & Co. (NYSE:MRK)? - Kalkine Media
Merck's drug for diabetes-related eye disease meets trial goal - reuters.com
Merck says remigromig met BRUNELLO vision endpoint, flags eye risks - Mugglehead Investment Magazine
Merck & Co. stock falls 1.86 percent as Q2 sales rise - AD HOC NEWS
Merck's experimental eye drug met its vision goal, but eye bleeding rates were higher than with the other drug - Stock Titan
Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck and Co. stock falls 1.9 percent before the bell - AD HOC NEWS
QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Merck stock falls 2.63 percent at the close - AD HOC NEWS
Merck pipeline seen driving potential re-rating as clinical catalysts approach - Proactive financial news
Merck & Co. stock gains as Japan clears Keytruda injection - AD HOC NEWS
Merck and Co. stock gains 0.94 percent ahead of the open - AD HOC NEWS
Merck stock gains 1.97 percent at the close - AD HOC NEWS
State Street Corp Has $15.57 Billion Position in Merck & Co., Inc. $MRK - MarketBeat
MRK|Merck & Co Inc|Price:150.910|Chg%:+1.410 - TradingKey
Merck & Co. stock falls 36.58 percent year to date - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Bought by Andra AP fonden - MarketBeat
Merck: Time To Trim, Overvalued, And Overbought (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck & Co Inc Share PriceMRK, RNS News, Articles, Quotes, & Charts (NYSE:MRK) - Proactive financial news
Merck & Co., Inc. (NYSE:MRK) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Could Merck & Co. (NYSE:MRK) Shift the Healthcare Stocks Narrative? - Kalkine Media
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer - Benzinga
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week - Seeking Alpha
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV - Business Wire
Nykredit A S Invests $92.32 Million in Merck & Co., Inc. $MRK - MarketBeat
What Merck is, what it makes, and why it matters in pharma - qz.com
Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise - finance.yahoo.com
Merck & Co Inc's Dividend Analysis - Yahoo Finance
California State Teachers Retirement System Has $484.72 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Company, Inc. (MRK) Stock Analysis: Evaluating A Healthcare Giant's Potential Upside - DirectorsTalk Interviews
Merck & Co., Inc. Target of Unusually Large Options Trading (NYSE:MRK) - MarketBeat
Merck & Co. stock gains as DBS lifts price target and Q2 2026 revenue grows - ad-hoc-news.de
0.04%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):